Skip to content
  • Investors & Media
      • Press Releases
      • Events & Presentations
      • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Investor Contacts
      • Email Alerts
  • Contact Us
  • Linkedin
  • 𝕏X
  • Youtube
  • Instagram
  • Facebook
Springworks
  • Who We Are
    • Leadership & Board
    • Mission & Values
    • DE&I
  • Focus Areas
    • Rare Oncology
    • BCMA Combinations in Multiple Myeloma
    • Biomarker-Defined Metastatic Solid Tumors
  • Pipeline
    • Overview
    • Nirogacestat
    • Mirdametinib
    • Investigator-Initiated Research
    • Medical Education & Grants
    • Key Scientific Presentations and Publications
  • Medicines
  • Patients
    • Desmoid Tumors
    • NF1-PN
    • Expanded Access Programs
  • Careers
    • Benefits

  • Investors & Media
      • Press Releases
      • Events & Presentations
      • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Investor Contacts
      • Email Alerts
  • Contact Us
  • Linkedin
  • 𝕏X
  • Youtube
  • Instagram
  • Facebook

State Regulations

Comprehensive Compliance Program

California Compliance Program Declaration

Wholesale Acquisition Cost Information for Colorado Prescribers

Wholesale Acquisition Cost Information for Connecticut Practitioners and Pharmacists

Vermont Pharmaceutical Marketer Price Disclosure

Springworks Logo

  • Linkedin
  • 𝕏X
  • Youtube
  • Instagram
  • Facebook
      • Who We Are
        • Leadership & Board
        • Mission & Values
        • DE&I
        • Compliance & Ethics
      • Focus Areas
        • Rare Oncology
        • BCMA Combinations in Multiple Myeloma
        • Biomarker-Defined Metastatic Solid Tumors
      • Pipeline
        • Nirogacestat
        • Mirdametinib
        • Investigator-Initiated Research
        • Medical Education and Grants
        • Key Scientific Presentations and Publications
      • Careers
        • View Opportunities
      • Medicines
      • Patients
        • Desmoid Tumors
        • NF1-PN
        • Expanded Access Programs
      • Contact
      • Investors & Media
        • Press Releases
        • Events & Presentations
        • Corporate Governance
        • Financial Information
        • Stock Information
        • Investor Resources
  • Privacy Policy
  • Consumer Health Data Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2025 SpringWorks Therapeutics, Inc. All rights reserved.

You are now leaving springworkstx.com, a website provided by SpringWorks Therapeutics. This link will take you to a different site to which this Privacy Policy and Terms of Use do not apply.

Ok Cancel

You are now being directed to additional information from SpringWorks Therapeutics.

Additional Information Cancel

You have selected a link to an article written and published by persons not affiliated with SpringWorks Therapeutics. The views expressed in the article are those of the author and do not reflect the views of SpringWorks Therapeutics. Additionally, the information contained in these articles may not be current. SpringWorks Therapeutics disavows any obligation to correct or to update the information contained in these articles.

Ok Cancel
Close